Paroxetine markedly increases plasma concentrations of ophthalmic timolol; cyp2d6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops

Mäenpää J., Volotinen-Maja M., Kautiainen H., Neuvonen M., Niemi M., Neuvonen P.J., Backman J.T.

2014
Drug Metabolism and Disposition

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Santen Oy, Tampere, Finland; Medcare Oy, Äänekoski, Finland; Department of Clinical Pharmacology, University of Helsinki, Helsinki University Central Hospital, P.O. Box 705, HUS, Helsinki, FI- 00029, Finland

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.

Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.

Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.

View all Glaucoma publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022